Cargando…

Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease

Parkin and α-synuclein are two key proteins involved in the pathophysiology of Parkinson’s disease (PD). Neurotoxic alterations of α-synuclein that lead to the formation of toxic oligomers and fibrils contribute to PD through synaptic dysfunction, mitochondrial impairment, defective endoplasmic reti...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Daniel Aghaie, Schmidt, Sissel Ida, Blaabjerg, Morten, Meyer, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911026/
https://www.ncbi.nlm.nih.gov/pubmed/33572534
http://dx.doi.org/10.3390/cells10020283
_version_ 1783656250058211328
author Madsen, Daniel Aghaie
Schmidt, Sissel Ida
Blaabjerg, Morten
Meyer, Morten
author_facet Madsen, Daniel Aghaie
Schmidt, Sissel Ida
Blaabjerg, Morten
Meyer, Morten
author_sort Madsen, Daniel Aghaie
collection PubMed
description Parkin and α-synuclein are two key proteins involved in the pathophysiology of Parkinson’s disease (PD). Neurotoxic alterations of α-synuclein that lead to the formation of toxic oligomers and fibrils contribute to PD through synaptic dysfunction, mitochondrial impairment, defective endoplasmic reticulum and Golgi function, and nuclear dysfunction. In half of the cases, the recessively inherited early-onset PD is caused by loss of function mutations in the PARK2 gene that encodes the E3-ubiquitin ligase, parkin. Parkin is involved in the clearance of misfolded and aggregated proteins by the ubiquitin-proteasome system and regulates mitophagy and mitochondrial biogenesis. PARK2-related PD is generally thought not to be associated with Lewy body formation although it is a neuropathological hallmark of PD. In this review article, we provide an overview of post-mortem neuropathological examinations of PARK2 patients and present the current knowledge of a functional interaction between parkin and α-synuclein in the regulation of protein aggregates including Lewy bodies. Furthermore, we describe prevailing hypotheses about the formation of intracellular micro-aggregates (synuclein inclusions) that might be more likely than Lewy bodies to occur in PARK2-related PD. This information may inform future studies aiming to unveil primary signaling processes involved in PD and related neurodegenerative disorders.
format Online
Article
Text
id pubmed-7911026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79110262021-02-28 Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease Madsen, Daniel Aghaie Schmidt, Sissel Ida Blaabjerg, Morten Meyer, Morten Cells Review Parkin and α-synuclein are two key proteins involved in the pathophysiology of Parkinson’s disease (PD). Neurotoxic alterations of α-synuclein that lead to the formation of toxic oligomers and fibrils contribute to PD through synaptic dysfunction, mitochondrial impairment, defective endoplasmic reticulum and Golgi function, and nuclear dysfunction. In half of the cases, the recessively inherited early-onset PD is caused by loss of function mutations in the PARK2 gene that encodes the E3-ubiquitin ligase, parkin. Parkin is involved in the clearance of misfolded and aggregated proteins by the ubiquitin-proteasome system and regulates mitophagy and mitochondrial biogenesis. PARK2-related PD is generally thought not to be associated with Lewy body formation although it is a neuropathological hallmark of PD. In this review article, we provide an overview of post-mortem neuropathological examinations of PARK2 patients and present the current knowledge of a functional interaction between parkin and α-synuclein in the regulation of protein aggregates including Lewy bodies. Furthermore, we describe prevailing hypotheses about the formation of intracellular micro-aggregates (synuclein inclusions) that might be more likely than Lewy bodies to occur in PARK2-related PD. This information may inform future studies aiming to unveil primary signaling processes involved in PD and related neurodegenerative disorders. MDPI 2021-01-31 /pmc/articles/PMC7911026/ /pubmed/33572534 http://dx.doi.org/10.3390/cells10020283 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Madsen, Daniel Aghaie
Schmidt, Sissel Ida
Blaabjerg, Morten
Meyer, Morten
Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title_full Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title_fullStr Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title_full_unstemmed Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title_short Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
title_sort interaction between parkin and α-synuclein in park2-mediated parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911026/
https://www.ncbi.nlm.nih.gov/pubmed/33572534
http://dx.doi.org/10.3390/cells10020283
work_keys_str_mv AT madsendanielaghaie interactionbetweenparkinandasynucleininpark2mediatedparkinsonsdisease
AT schmidtsisselida interactionbetweenparkinandasynucleininpark2mediatedparkinsonsdisease
AT blaabjergmorten interactionbetweenparkinandasynucleininpark2mediatedparkinsonsdisease
AT meyermorten interactionbetweenparkinandasynucleininpark2mediatedparkinsonsdisease